Suppr超能文献

胸腺素组分5的免疫调节作用及治疗特性

Immunomodulation and therapeutic characterization of thymosin fraction five.

作者信息

Talmadge J E, Uithoven K A, Lenz B F, Chirigos M

出版信息

Cancer Immunol Immunother. 1984;18(3):185-94. doi: 10.1007/BF00205510.

DOI:10.1007/BF00205510
PMID:6239686
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11039068/
Abstract

In this report we describe the characterization of the immunomodulatory efficiency and therapeutic properties of thymosin fraction five (F5). We consistently observed the immunostimulation of T-cell activity in assays of allogeneic mixed lymphocyte response (MLR) and the development of cytotoxic effector cells in an allogeneic mixed lymphocyte tumor response-cell-mediated cytotoxicity assay (MLTR-CMC). No induction of suppressor cell activity was observed. Thymosin F5 also acted successfully as an adjuvant when admixed with irradiated tumor cells. We were unable to demonstrate either NK cell or macrophage activation by thymosin F5. Therapeutic protocols using thymosin F5 and directed against pre-existing experimental and spontaneous metastases, had a significant immunotherapeutic potential.

摘要

在本报告中，我们描述了胸腺素组分五（F5）的免疫调节效率和治疗特性。在异体混合淋巴细胞反应（MLR）试验中，我们始终观察到T细胞活性的免疫刺激作用，并且在异体混合淋巴细胞肿瘤反应-细胞介导的细胞毒性试验（MLTR-CMC）中观察到细胞毒性效应细胞的产生。未观察到抑制细胞活性的诱导。当与经照射的肿瘤细胞混合时，胸腺素F5也成功地起到了佐剂的作用。我们未能证明胸腺素F5对NK细胞或巨噬细胞有激活作用。使用胸腺素F5并针对预先存在的实验性和自发性转移瘤的治疗方案具有显著的免疫治疗潜力。

相似文献

1
Immunomodulation and therapeutic characterization of thymosin fraction five.胸腺素组分5的免疫调节作用及治疗特性
Cancer Immunol Immunother. 1984;18(3):185-94. doi: 10.1007/BF00205510.
2
The effect of experimental conditions on the assessment of T cell immunomodulation by biological response modifiers (thymosin fraction five).实验条件对生物反应调节剂（胸腺素组分 5）评估 T 细胞免疫调节的影响。
Immunopharmacology. 1984 Feb;7(1):17-26. doi: 10.1016/0162-3109(84)90004-3.
3
Thymosin: immunomodulatory and therapeutic characteristics.胸腺素：免疫调节及治疗特性
Prog Clin Biol Res. 1984;161:457-65.
4
Immunoregulatory effects of fraction 5 thymus peptides. I. Thymosin alpha 1 enhances while thymosin beta 4 suppresses the human autologous and allogeneic mixed lymphocyte reaction.
Immunopharmacology. 1987 Apr;13(2):133-41. doi: 10.1016/0162-3109(87)90050-6.
5
The biological effect of three thymosin fraction 5 polypeptides in the murine mixed lymphocyte reaction.三种胸腺素5组分多肽在小鼠混合淋巴细胞反应中的生物学效应
Immunology. 1985 Apr;54(4):723-30.
6
Mechanism of action of thymosin. I. Thymosin fraction 5 increases lymphokine production by mature murine T cells responding in a mixed lymphocyte reaction.胸腺素的作用机制。I. 胸腺素5组分可增加成熟小鼠T细胞在混合淋巴细胞反应中产生淋巴因子。
J Immunol. 1985 Feb;134(2):1032-8.
7
Immunomodulatory and therapeutic properties of bestatin in mice.贝司他汀在小鼠体内的免疫调节和治疗特性。
Cancer Res. 1986 Sep;46(9):4505-10.
8
Suppressive effect of thymosin fraction 5 on proliferation of cultured human T lymphocytes.胸腺素5组分对培养的人T淋巴细胞增殖的抑制作用。
Immunopharmacology. 1986 Dec;12(3):233-40. doi: 10.1016/0162-3109(86)90007-x.
9
High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.高剂量的胸腺肽α1可增强联合化学免疫疗法对小鼠B16黑色素瘤的抗肿瘤疗效。
Anticancer Res. 1998 Sep-Oct;18(5A):3571-8.
10
Thymosin-induced differentiation of murine thymocytes in allogeneic mixed lymphocyte cultures.
Ann N Y Acad Sci. 1975 Feb 28;249:145-53. doi: 10.1111/j.1749-6632.1975.tb29064.x.

引用本文的文献

1
Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?前胸腺素α与免疫反应：我们离潜在的临床应用还有多远？
Vitam Horm. 2016;102:179-207. doi: 10.1016/bs.vh.2016.04.008. Epub 2016 May 27.
2
Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers.生物反应调节剂的免疫调节和免疫治疗特性比较
Springer Semin Immunopathol. 1985;8(4):429-43. doi: 10.1007/BF01857395.
3
Thymosins and anti-thymosins: properties and clinical applications.胸腺素与抗胸腺素：特性及临床应用
Med Oncol Tumor Pharmacother. 1986;3(3-4):211-21. doi: 10.1007/BF02934997.
4
Thymic hormones--a clinical update.胸腺激素——临床最新进展
Springer Semin Immunopathol. 1986;9(1):1-18. doi: 10.1007/BF00201901.

本文引用的文献

1
ANTIGENIC PROPERTIES OF LYMPHOMAS INDUCED BY THE MOLONEY AGENT.莫洛尼氏因子诱导的淋巴瘤的抗原特性
J Natl Cancer Inst. 1964 Mar;32:547-68.
2
A transplantable mast-cell neoplasm in the mouse.一种可移植的小鼠肥大细胞瘤。
J Natl Cancer Inst. 1957 Apr;18(4):587-601.
3
Tumor cytotoxicity of rat alveolar macrophages activated in vitro by endotoxin.内毒素体外激活的大鼠肺泡巨噬细胞的肿瘤细胞毒性
J Reticuloendothel Soc. 1980 Mar;27(3):269-79.
4
Induction of terminal deoxynucleotidyl transferase and Lyt antigens with thymosin: identification of multiple subsets of prothymocytes in mouse bone marrow and spleen.胸腺素诱导末端脱氧核苷酸转移酶和Lyt抗原：小鼠骨髓和脾脏中前胸腺细胞多个亚群的鉴定。
Proc Natl Acad Sci U S A. 1981 Apr;78(4):2469-73. doi: 10.1073/pnas.78.4.2469.
5
Macrophage content of metastatic and nonmetastatic rodent neoplasms.转移性和非转移性啮齿动物肿瘤中的巨噬细胞含量
J Immunol. 1981 Jun;126(6):2245-8.
6
Resistance to L1210 mouse leukemia cells in moderately protein-malnourished BALB/c mice treated in vivo with thymosin fraction V.用胸腺素组分V体内治疗的中度蛋白质营养不良BALB/c小鼠对L1210小鼠白血病细胞的抗性。
Cancer Res. 1982 Jun;42(6):2139-45.
7
Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers.建立用于评估生物反应调节剂的筛查程序的实际考量因素。
J Biol Response Mod. 1984;3(1):88-109.
8
Enhancement of murine thymocyte cytotoxic T cell responses by thymosin.
Immunopharmacology. 1983 Jun;6(1):65-74. doi: 10.1016/0162-3109(83)90017-6.
9
Regulation of in vitro generation of cell-mediated cytotoxicity. II. Characterization of thymosin-induced suppressor T cells.体外细胞介导细胞毒性生成的调控。II. 胸腺素诱导的抑制性T细胞的特性
Immunopharmacology. 1980 Dec;2(4):301-12. doi: 10.1016/0162-3109(80)90014-4.
10
Regulation of in vitro generation of cell-mediated cytotoxicity. In vitro induction of suppressor T lymphocytes by thymosin.
J Reticuloendothel Soc. 1980 Aug;28(2):141-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验